ASP 8477

A novel potent, highly selective fatty acid amide hydrolase (FAAH) inhibitor with IC50 of 0.99, 1.65 and 57.3 nM for human FAAH-1, FAAH-1 (P129T) and FAAH-2, respectively; displays no appreciable binding affinity to or inhibition against a panel of 65 receptors, ion channels and transporters, including CB1, CB2 receptors and MAGL; elevates AEA concentrations in both plasma and brain in adolescent rats, significantly improves mechanical allodynia and thermal hyperalgesia in capsaicin-induced secondary hyperalgesia model (0.3-3mg/kg, p.o). Pain Phase 2 Discontinued

References 1. Watabiki T, et al. Eur J Pharmacol. 2017 Nov 15;815:42-48. 2. Bradford D, et al. Pain Med. 2017 Dec 1;18(12):2388-2400. View Related Products by Target FAAH Pain